JAMA· 2017Q1· Clinical trial

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner, William L. Read et al.

2,618citations
Q1SCImago
2017year

Short summary

Adding Tumor-Treating Fields (TTFields) to maintenance temozolomide chemotherapy significantly improved both progression-free survival (6.7 vs. 4.0 months) and overall survival (20.9 vs. 16.0 months) in glioblastoma patients.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine